# reload+after+2024-01-22 16:47:14.565732
address1§500 Rutherford Avenue
address2§Third Floor
city§Charlestown
state§MA
zip§02129
country§United States
phone§617 337 4680
website§https://www.solidbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
fullTimeEmployees§87
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Ian F. Smith A.C.A., C.P.A.', 'age': 57, 'title': 'Executive Chair', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 75000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander G. Cumbo', 'age': 52, 'title': 'President, CEO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1820760, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ilan  Ganot', 'age': 49, 'title': 'Co-founder, Strategic Advisor to the CEO & Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1363292, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David Tyronne Howton Jr., J.D.', 'age': 51, 'title': 'COO & Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 1401200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gilad David Hayeem', 'age': 55, 'title': 'Co-Founder', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Annie  Ganot', 'title': 'Co-Founder & Head of Patient Advocacy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Andrey Juan Zarur Ph.D.', 'age': 52, 'title': 'Co-Founder', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 90169, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin  Tan C.F.A.', 'age': 46, 'title': 'CFO & Treasurer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen J. Di Palma M.B.A.', 'age': 64, 'title': 'Treasurer & Principal Accounting Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul  Herzich', 'age': 45, 'title': 'Chief Technology Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.673
priceToSalesTrailing12Months§Infinity
currency§USD
dateShortInterest§1702598400
forwardEps§-3.64
exchange§NMS
quoteType§EQUITY
shortName§Solid Biosciences Inc.
longName§Solid Biosciences Inc.
firstTradeDateEpochUtc§1516977000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§df2633a7-0b74-3fde-a30e-2e49f7e866ef
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§5.0
targetMeanPrice§7.2
targetMedianPrice§8.0
recommendationMean§2.6
recommendationKey§hold
numberOfAnalystOpinions§5
quickRatio§9.034
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
